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Abstract
Introduction: The article presents the results of the study of the maximum tolerant dose (MTD) and the analgesic 
activity of peptide PT1 isolated from Alopecosa marikovskyi spider venom. PT1 is the first compound of polypeptide 
nature, capable of exerting a selective modulating effect on purinergic P2X3 receptors.
Materials and methods: The study was conducted on 174 ICR mice. The analgesic activity of the peptide was evalu-
ated in a thermal hypersensitivity test triggered by CFA and in a model of chemical irritation.
Results and discussion: The determined MTD for the peptide PT1 when administered intravenously provides evidence 
to attribute it to low-toxic compounds. The maximum analgesic activity of PT1 using the biomodel of hypersensitivity 
induced by CFA when tested 15 minutes after the administration was recorded at doses of 0.1 and 0.5 mg/kg. In the 
visceral pain test, the maximum analgesic activity 15 minutes after the administration of the chemical stimulus was 
observed at a dose of 0.01 mg/kg.
Conclusions: According to the results of testing peptide PT1, it is shown that it belongs to low-toxic compounds, has a 
pronounced analgesic activity in a wide range of doses of 0.0001–10 mg/kg.
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Introduction
Nowadays pain is one of the main reasons for seeking 
medical help. The perception of pain is an important pro-
tective ability of the body, informing us of the harmful 
effects that damage tissues and organs or pose a potential 
danger to the body. Pain is not just a symptom of many 
acute and chronic inflammatory pathologies, but also a 
complex psychophysiological phenomenon involving the 
formation of emotions, motor, humoral and hemodyna-
mic manifestations (Chiao and Boretsky 2017, Grant et 
al. 2018, Linton and Shaw 2011, Monaghan et al. 2018). 
Pain response is a systemic response of the body, and 
this indicates the extreme complexity of its mechanisms. 
It was established that the pain arising in case of tissue 
damage has a phase character: first, it is acute and well 
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localized, and then after a few seconds, it is replaced by 
diffuse, less acute and more emotionally colored. Such 
dynamics of pain is associated with the participation of 
various afferent systems in conducting nociceptive im-
pulses (Al Darwish Alopecosa marikovskyi et al. 2016, 
Dyachenko et al. 2018, Palikova et al. 2018a, Palikova et 
al. 2018b, Sharkey 2013, Sharma et al. 2015).
Existing painkillers can regain control of pain sensitiv-
ity in only ~ 30% of patients with injuries of the nervous 
system. A significant number of elderly people, patients 
with oncological diseases complain of daily pain. In ad-
dition, chronic pain leads to serious economic losses due 
to a decrease in the ability to work of a significant part 
of the population. Patients with chronic pain syndrome 
often become depressed, restless, and suffer from sleep 
disorders. The quality of life of such persons is drastical-
ly reduced (Avez-Couturier and Wood 2016, Mercadante 
2017, Vickers et al. 2017). Based on the above, the search 
for and study of new drugs with an analgesic activity is a 
relevant area for scientific research.
It turned out that natural poisons can serve as a source 
of powerful new analgesics (Lewis and Garcia 2003). In 
2012, in a targeted search for natural analgesic compounds 
in the laboratory of neuroreceptors and neuroregulators of 
the IBCh RAS from the Central Asian wolf spider, puro-
toxin PT1, a peptide that inhibits one of the most impor-
tant subtypes of human pain receptors was isolated and 
comprehensively characterized. The amino acid sequence 
PT1 (protein sequence data in the UniProt knowledge 
base [http://www.uniprot.org] under accession number 
P86269) was determined using automated Edman degra-
dation and verified by matrix-activated laser desorption 
mass spectrometry/ionization and specific proteolysis.
Recombinant PT1 was produced by E. Coli as a cleaved 
thioredoxin fusion, and the equivalent of the native pep-
tide was proven by analytical chromatography, MC, and 
biological testing. It was shown that PT1 in nanomolar 
concentrations significantly reduces ATP receptor activa-
tion, stabilizing the receptor desensitization stage (Grish-
in et al. 2010).
Materials and methods
The PT1 peptide under study consists of 35 amino acid 
residues, and can be isolated by chromatographic methods 
from venom of the spider Alopecosa marikovskyi, or ob-
tained by peptide synthesis, as well as by genetic enginee-
ring methods. PT1 has the following amino acid sequence:
Gly1-Tyr2-Cys3-Ala4-Glu5-Lys6-Gly7-Ile8-Arg9-
Cys10-Asp11-Asp12-Ile13-His14-Cys15-Cys16-Thr17-
Gly18-Leu19-Lys20-Cys21-Lys22-Cys23-Asn24-Ala25-
Ser26-Gly27-Tyr28-Asn29-Cys30-Val31-Cys32-Arg33-
Lys34-Lys35
The recombinant peptide PT1 modulates the activity of 
the purinergic receptors P2X3 and exhibits an analgesic 
activity in animal models (Grishin et al. 2010, Kabanova 
et al. 2012, RF Patent No. 2422459 2011). The recombi-
nant peptide PT1 was provided by the Laboratory of Neu-
roreceptors and Neuroregulators of the IBCh RAS for in 
vivo preclinical studies.
Maximum tolerant dose study
The study of the maximum tolerant dose (MTD) and the 
anesthetic activity of the PT1 polypeptide were carried 
out in compliance with the requirements of the current 
Guidelines for the preclinical study of new pharmacolo-
gical substances and according to the Rules of Laboratory 
Practice in the Russian Federation (National Standard of 
the Russian Federation, GOST 33647-2015). The proce-
dures with animals were reviewed and approved by the 
Bioethical Commission of the Institute of Bioorganic 
Chemistry of RAS (Minutes No. 330/12).
The toxicity class of the test drug is determined in ac-
cordance with the GHS (Globally Harmonized System of 
Classification and Labeling of Chemicals).
To determine the MTD of the PT1 peptide after its 
single administration to mice, an intravenous route of 
administration was chosen. The study used female ICR 
outbred mice. Observation of the animals to detect ab-
normalities in health and mortality was performed daily 
in the morning. A detailed clinical examination of each 
animal was carried out 10–60 minutes after the admin-
istration of the substance, then daily in the first 48 hours 
and weekly thereafter.
Hypersensitivity induced by complete Freund’s adjuvant
Thermal hypersensitivity was modeled by intraplantar ad-
ministration of a mixture of CFA (Sigma-Aldrich, USA) 
and 0.9% sodium chloride solution (1:1) 24 hours before 
the injection of the peptide and the comparator was admi-
nistered, followed by placing the animal on a thermostat-
ted surface (53 °C) until a characteristic response in the 
form of shaking the hind paw, in which local inflammati-
on was induced. In the control group, animals received a 
0.9% sodium chloride solution. Testing on the thermostat-
ted surface was carried out at different time points after 
the injection of substances (15 min, 1 h, 4 h, 24 h). For the 
recombinant peptide PT1, an intravenous route of admi-
nistration was chosen. The selected bio-model of thermal 
hypersensitivity provoked by CFA is the basic model for 
evaluating the analgesic activity of substances.
Method to evaluate visceral pain – writhing test
To simulate visceral pain, male mice were intraperito-
neally (i.p.) injected with a 0.6% solution of acetic acid 
after prior administration of the test substances (1 h, 4 h, 
24 h beforehand). In the control group, animals received 
a 0.9% sodium chloride solution. The testing took into ac-
count the time of the first specific nociceptive cramp-like 
response, as well as their number for 15 minutes.
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The results of the obtained studies were processed statis-
tically and presented in the form of tables and figures. When 
performing statistical calculations, the normality of the dis-
tribution was preliminarily estimated using Shapiro-Wilks 
tests. In the case of a normal distribution of quantitative 
variables, a Duncan’s test (univariate analysis of variance: 
a posteriori multiple comparisons) was used for independ-
ent samples to compare the two groups. When comparing 
several groups with an abnormal distribution of the stud-
ied traits, the nonparametric Kruskal-Wallis criterion was 
used, which is a rank analysis of variations. The difference 
in the dynamics of treatment was assessed using Student’s 
t-test for related samples. The difference between the ex-
perimental groups was considered significant at p≤0.05. All 
calculations were done on a personal computer using the 
statistical program STATISTICA 7.0 (StatSoft, USA).
Experiments were partially carried out using the equip-
ment provided by the IBCh core facility, supported by 
Russian Ministry of Education and Science, grant RFME-
FI62117X0018).
Results and discussion
Initially, the study of MTD of the PT1 peptide after in-
travenous administration was started with a dose of 50 
mg/kg, and further the dose was increased, since no de-
ath of the experimental animals was observed. Increasing 
the dose to 300 mg/kg did not cause any manifestation of 
toxic effects. At a dose of 900 mg/kg in mice, an intense 
licking of the site of injection was observed, indicating 
an irritant effect. Subsequently, the dose was increased to 
2000 mg/kg, at which the death of all animals was recor-
ded. Reducing the dose to 1800 mg/kg also caused the 
death of experimental animals. When the dose was redu-
ced to 1400 mg/kg, PT1 caused pronounced toxic effects, 
while death of one animal (12.5%) out of eight was obser-
ved. Increasing the dose to 1600 mg/kg caused the death 
of two (40%) animals out of five, and pronounced toxic 
effects were observed after administration. The range of 
clinical signs of intoxication in determining MTD in ex-
perimental animals is given in Table 1.
The average body weight and weight gain in exper-
imental animals with intravenous administration of the 
peptide PT1 at doses of 1400 and 1600 mg/kg are present-
ed in Table 2. With intravenous administration of the pep-
tide PT1, the body weight of animals treated with doses of 
1400 and 1600 mg/kg was 23.4±0.9 (n=8) and 22.3±0.4 
(n=5), respectively. The dynamics of body weight gain on 
the 7th and 14th days after administration of the test pep-
tide showed that the animals completely recovered from 
the toxic effects of large doses of the drug over the study 
period. No significant differences between the groups of 
mice that received different doses were identified.
In surviving animals, 14 days after the administration 
of the peptide PT1, planned necropsy was performed. 
Necropsy revealed no abnormalities in the internal organs, 
which indicated low toxicity of the substance. Thus, as a 
result of the study, MTD of the PT1 peptide was deter-
mined for female CD-1 mice after intravenous adminis-
tration, which was 1400 mg/kg. In accordance with GOST 
12.1.007.-76 and the OECD classification of chemical 
substances, the results of the determination of the MTD of 
the PT1 peptide upon its intravenous administration give 
grounds for attributing it to low-toxic compounds.
Subsequently, the PT1 polypeptide was tested in a 
thermal hypersensitivity test triggered by CFA. PT1 was 
administered intravenously at doses of 0.001, 0.01, 0.05, 
0.1, 0.5, 1, 2 mg/kg to ICR mice 21–24 hours after sim-
ulating local inflammation induced by CFA. Testing was 
carried out 15 minutes after the administration of PT1. 
The control group of animals received saline (solvent). 
The results of the study are presented in Figure 1.
At a dose of 0.001 mg/kg (7.4±0.3 s), no significant 
differences from the control group were observed. In-
Table 1. The Range of Clinical Signs of Intoxication in Deter-
mining the Maximum Tolerant Dose of Peptide PT1.
Clinical signs Observation Day
I/v injection of peptid РТ1:
900 mg/
kg (n=3)
1400 mg/
kg (n=8)
1600 
mg/kg 
(n=5)
1800 
mg/kg 
(n=3)
Animal death
day 1 0 1 1 0
day 2 0 0 1 3
Total: 0 1 2 3
Hunched pose, 
piloerection
day 1 2 5 3 3
day 2 1 3 2 0
Total: 3 8 5 3
Lethargy, 
decreased 
motor activity
day 1 1 5 3 3
day 2 1 3 2 0
Total: 2 8 5 3
Impaired 
hearing and 
pain sensitivity
day 1 2 3 4 3
day 2 1 0 1 0
Total: 3 3 5 3
Convulsions, 
muscle 
stiffness
day 1 0 5 3 3
day 2 0 1 2 0
Total: 0 6 5 3
Heavy 
intermittent 
breathing, 
rapid breathing
day 1 1 1 3 3
day 2 0 0 2 0
Total: 1 1 5 3
Note: here and below n – the number of animals in the group.
Table 2. Body Weight and Weight Gain in Mice CD-1 after a 
Single Injection of Peptide PT1.
Body weight of experimental 
animals (g) and weight gain (%)
i/v injection of peptide РТ1:
1400 mg/kg 1600 mg/kg
Body weight on the 1st day of 
administration, g 23.4±0.9 (n=8) 22.3±0.4 (n=5)
Body weight on the 7th day of 
administration, g 24.3±1.1 (n=7) 23.2±0.2 (n=3)
Weight gain on the 7th day of 
administration,% 3.9±2.3 (n=7) 14.8±4.0 (n=3)
Body weight on the 14th day of 
administration, g 25.8±1.1 (n=7) 24.1±0.5 (n=3)
Weight gain on the 14th day of 
administration,% 12.0±2.8 (n=7) 24.9±4.7 (n=3)
Palikova YuA et al.: Maximum tolerant dose and analgesic activity of  PT1 peptide.40
travenous administration of PT1 in the dose range from 
0.01 mg/kg (9.5±0.8 s) to 1 mg/kg (9.6±0.3 s) showed 
significant differences in the time that animals spent on 
a thermostatically controlled plate relative to the control 
group treated with saline (7.3±0.3 s). The maximum anal-
gesic activity of PT1 using the biomodel of hypersensitiv-
ity triggered by CFA in tests 15 minutes after the adminis-
tration was recorded at doses of 0.1 and 0.5 mg/kg.
In addition, the PT1 peptide was examined in a vis-
ceral pain test. The results of the study are presented in 
Figure 2. The test peptide was administered intravenously 
at doses of 0.00001, 0.0001, 0.0005, 0.001, 0.01, 0.1, 0.5, 
1 and 10 mg/kg to ICR mice; the study was performed 15 
minutes after peptide administration. The control group of 
animals received saline (solvent).
In the visceral pain test, the number of specific nocic-
eptive “writhing” type responses and the time of the first 
“writhe” after the administration of the stimulus (0.6% 
acetic acid) were recorded. In the study of the analgesic 
activity of the PT1 peptide 15 minutes after the adminis-
tration, no significant differences between the groups in 
terms of the “time of the first writhe” indicator after the 
injection of the chemical stimulus were detected relative 
to the control group treated with saline. Statistical anal-
ysis of the parameter “total number of writhes over 15 
minutes” revealed a significant difference in all studied 
Figure 1. The study of the analgesic activity of the peptide PT1 on the biomodel of thermal hypersensitivity provoked by CFA The 
data are presented as arithmetic mean ± error of the arithmetic mean, the number of animals in each group is not less than 9, p≤0.05 
when compared with the “0.9% NaCl” group; statistical analysis was performed using the ANOVA-2 test (Post-Hoc Duncan-test).
Figure 2. The study of the analgesic activity of the peptide PT1 in the test of visceral pain. The data are presented as the arithmetic 
mean ± error of the arithmetic mean, the number of animals in the group is not less than 6, p≤0.05 when compared with the “0.9% 
NaCl” group; statistical analysis was performed using the ANOVA-2 test (Post-Hoc Duncan-test).
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doses relative to the control group (39.3±1.5), except for 
the minimum dose of 0.00001 mg/kg (35.7±2.1). A signif-
icant difference in the dose of 0.00001 mg/kg relative to 
the other studied doses was observed.
The results of testing the peptide PT1 by intravenous 
administration to ICR mice showed that the maximum an-
algesic activity 15 minutes after the injection of the chem-
ical stimulus occurs at a dose of 0.01 mg/kg.
Conclusions
The results of the study showed that the PT1 peptide sho-
wed pronounced activity in vivo in a wide range of doses 
(0.0001–10 mg/kg). The peptide significantly reduced the 
pain response in both the thermal hypersensitivity test trig-
gered by CFA at doses of 0.01–1 mg/kg and in the visceral 
pain model at doses of 0.0001–10 mg/kg. Thus, according 
to the results of testing of the peptide PT1, it is shown that 
it belongs to low-toxic compounds and has a pronounced 
analgesic activity, which has practical value when creating 
further effective analgesics of a new generation.
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